Effect of rosuvastatin or its combination with omega-3 fatty acids on circulating CD34(+) progenitor cells and on endothelial colony formation in patients with mixed dyslipidaemia.

Autor: Chantzichristos VG; Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, 45110 Ioannina, Greece., Agouridis AP; Department of Internal Medicine, School of Medicine, University of Ioannina, 45110 Ioannina, Greece., Moutzouri E; Department of Internal Medicine, School of Medicine, University of Ioannina, 45110 Ioannina, Greece., Stellos K; Department of Cardiology and Institute of Cardiovascular Regeneration, Goethe University Frankfurt, Frankfurt am Main, 60590, Germany; German Centre of Cardiovascular Research (DZHK), Rhein-Main Partner Site, Frankfurt, Germany., Elisaf MS; Department of Internal Medicine, School of Medicine, University of Ioannina, 45110 Ioannina, Greece., Tselepis AD; Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, 45110 Ioannina, Greece. Electronic address: atselep@uoi.gr.
Jazyk: angličtina
Zdroj: Atherosclerosis [Atherosclerosis] 2016 Aug; Vol. 251, pp. 240-247. Date of Electronic Publication: 2016 Jul 01.
DOI: 10.1016/j.atherosclerosis.2016.06.047
Abstrakt: Background and Aims: Hypercholesterolaemia is associated with a reduced number of circulating progenitor cells, a defect that is restored by statin therapy. We studied the effect of rosuvastatin monotherapy or its combination with omega-3 polyunsaturated fatty acids (ω-3 PUFAs) on progenitor cell number and function in patients with mixed dyslipidaemia.
Methods: Fifty patients with mixed dyslipidaemia and fifty-five normolipidaemic, apparently healthy, age- and sex-matched volunteers participated in the study. Patients were randomized to receive a daily dose of either 40 mg rosuvastatin (R group, n = 26) or 10 mg rosuvastatin plus 2 g of ω-3 PUFAs (R + O group, n = 24). The number of circulating CD34(+) and CD34(+)/KDR(+) progenitor cells as well as the number of colony-forming units-endothelial cells (CFU-ECs) at 10 days of culture were assessed at baseline and 3 months post-treatment.
Results: The number of CD34(+) and CD34(+)/KDR(+) cells per 10,000 leukocytes as well as the number of CFU-ECs were significantly lower in both patient groups compared with healthy volunteers (all p = 0.03). A 3-month treatment with either R or R + O significantly increased circulating CD34(+) and CD34(+)/KDR(+) cells as well as the number of CFU-ECs compared with baseline (all p = 0.03). Importantly, the increase in the above parameters was inversely correlated with therapy-induced reduction in lipid parameters in both patient groups.
Conclusions: Patients with mixed dyslipidaemia exhibit low numbers of circulating CD34(+) and CD34(+)/KDR(+) cells as well as CFU-ECs in culture, a defect restored by 3-month treatment with either high-rosuvastatin dose or a combination of low-rosuvastatin dose with ω-3 PUFAs. The pathophysiological meaning of our results regarding the increased cardiovascular risk in these patients remains to be established.
(Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: